vs
Side-by-side financial comparison of CG Oncology, Inc. (CGON) and Moolec Science SA (MLEC). Click either name above to swap in a different company.
Moolec Science SA is the larger business by last-quarter revenue ($2.6M vs $2.3M, roughly 1.1× CG Oncology, Inc.). Moolec Science SA runs the higher net margin — -91.8% vs -1779.0%, a 1687.2% gap on every dollar of revenue.
CG Oncology, Inc. is a clinical-stage biotechnology company focused on developing innovative targeted immunotherapies for urological cancers including non-muscle invasive bladder cancer. It primarily operates in the U.S. market, advancing pipeline candidates to address unmet medical needs for patients with limited treatment options.
Moolec Science SA is a global agricultural biotechnology and food technology company specializing in molecular farming. It uses engineered crop platforms to produce sustainable, cost-competitive animal-derived proteins for use in alternative meat, dairy products and food ingredients, serving food manufacturers, agribusinesses and consumer goods brands across North America, Europe and Latin America.
CGON vs MLEC — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.3M | $2.6M |
| Net Profit | $-41.3M | $-2.4M |
| Gross Margin | — | -25.5% |
| Operating Margin | -2097.3% | -77.9% |
| Net Margin | -1779.0% | -91.8% |
| Revenue YoY | 409.2% | — |
| Net Profit YoY | -29.9% | — |
| EPS (diluted) | $-0.52 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.3M | — | ||
| Q3 25 | $1.7M | — | ||
| Q2 25 | $0 | — | ||
| Q4 24 | $456.0K | $2.6M | ||
| Q1 24 | $529.0K | — | ||
| Q3 23 | — | $1.7M |
| Q4 25 | $-41.3M | — | ||
| Q3 25 | $-43.8M | — | ||
| Q2 25 | $-41.4M | — | ||
| Q4 24 | $-31.8M | $-2.4M | ||
| Q1 24 | $-16.9M | — | ||
| Q3 23 | — | $-1.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | — | -25.5% | ||
| Q1 24 | — | — | ||
| Q3 23 | — | 12.7% |
| Q4 25 | -2097.3% | — | ||
| Q3 25 | -3069.0% | — | ||
| Q2 25 | — | — | ||
| Q4 24 | -8344.1% | -77.9% | ||
| Q1 24 | -4247.4% | — | ||
| Q3 23 | — | -130.3% |
| Q4 25 | -1779.0% | — | ||
| Q3 25 | -2629.5% | — | ||
| Q2 25 | — | — | ||
| Q4 24 | -6973.7% | -91.8% | ||
| Q1 24 | -3200.8% | — | ||
| Q3 23 | — | -91.4% |
| Q4 25 | $-0.52 | — | ||
| Q3 25 | $-0.57 | — | ||
| Q2 25 | $-0.54 | — | ||
| Q4 24 | $-0.47 | $-0.06 | ||
| Q1 24 | $-0.36 | — | ||
| Q3 23 | — | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $742.2M | $1.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $752.6M | $2.8M |
| Total Assets | $791.6M | $31.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $742.2M | — | ||
| Q3 25 | $680.3M | — | ||
| Q2 25 | $661.1M | — | ||
| Q4 24 | $742.0M | $1.9M | ||
| Q1 24 | $566.5M | — | ||
| Q3 23 | — | $853.6K |
| Q4 25 | $752.6M | — | ||
| Q3 25 | $687.6M | — | ||
| Q2 25 | $670.4M | — | ||
| Q4 24 | $733.4M | $2.8M | ||
| Q1 24 | $568.9M | — | ||
| Q3 23 | — | $8.9M |
| Q4 25 | $791.6M | — | ||
| Q3 25 | $729.9M | — | ||
| Q2 25 | $701.4M | — | ||
| Q4 24 | $754.8M | $31.4M | ||
| Q1 24 | $579.1M | — | ||
| Q3 23 | — | $22.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-36.2M | — |
| Free Cash FlowOCF − Capex | $-36.2M | — |
| FCF MarginFCF / Revenue | -1560.0% | — |
| Capex IntensityCapex / Revenue | 0.3% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-124.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-36.2M | — | ||
| Q3 25 | $-38.9M | — | ||
| Q2 25 | $-28.0M | — | ||
| Q4 24 | $-20.7M | — | ||
| Q1 24 | $-26.0M | — | ||
| Q3 23 | — | $-1.7M |
| Q4 25 | $-36.2M | — | ||
| Q3 25 | $-39.0M | — | ||
| Q2 25 | $-28.0M | — | ||
| Q4 24 | $-20.9M | — | ||
| Q1 24 | $-26.0M | — | ||
| Q3 23 | — | $-1.8M |
| Q4 25 | -1560.0% | — | ||
| Q3 25 | -2340.4% | — | ||
| Q2 25 | — | — | ||
| Q4 24 | -4577.0% | — | ||
| Q1 24 | -4919.5% | — | ||
| Q3 23 | — | -106.2% |
| Q4 25 | 0.3% | — | ||
| Q3 25 | 5.8% | — | ||
| Q2 25 | — | — | ||
| Q4 24 | 45.8% | 4.4% | ||
| Q1 24 | 2.3% | — | ||
| Q3 23 | — | 6.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
